<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986076</url>
  </required_header>
  <id_info>
    <org_study_id>08-010</org_study_id>
    <nct_id>NCT00986076</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery</brief_title>
  <official_title>Randomized Clinical Trial Evaluating Anti-inflammatory Effect of Low Molecular-Weight Heparin in Pediatric Cataract and Intraocular Lens Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iladevi Cataract and IOL Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iladevi Cataract and IOL Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intraocular infusion of low-molecular weight
      heparin (enoxaparin) influences postoperative inflammation following pediatric cataract
      surgery with intraocular lens (IOL) implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in cataract surgery in children, postoperative inflammation is a significant
      complication following pediatric cataract surgery. Any drug that prevents or decreases this
      inflammation would be beneficial.

      Heparin has anti-inflammatory and antiproliferative effects as well as anticoagulant
      properties. Several studies on animal and adult human eyes show that adding heparin to the
      irrigating solution during cataract surgery results in less disturbance of the blood-aqueous
      barrier and helps prevent posterior capsule opacification (PCO).

      A prospective, randomized, controlled and masked study is mandatory to evaluate the
      anti-inflammatory effect of Low-molecular weight Heparin for pediatric cataract surgery
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior Segment Inflammation</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anterior Segment inflammation</measure>
    <time_frame>1 month, 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Enoxaparin infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Congenital Cataract Surgery with IOL implantation
Intraocular infusion of Enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced Salt Solution Infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin 40 mg / 500 ml in Balanced Salt Solution</description>
    <arm_group_label>Enoxaparin infusion</arm_group_label>
    <other_name>Clexane(Aventis)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balanced Salt Solution</intervention_name>
    <description>Intraocular infusion of Balanced Salt solution</description>
    <arm_group_label>Balanced Salt Solution Infusion</arm_group_label>
    <other_name>BSS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children (0-15 years) with congenital cataract scheduled for surgery with IOL
             implantation and informed consent from the parents/legal guardian

        Exclusion Criteria:

          -  Preoperative: Associated ocular anomalies (uveitis, microphthalmos, persistent fetal
             vasculature, aniridia, glaucoma, iris coloboma), traumatic cataract

          -  Intraoperative: Inability to implant IOL in the capsular bag, intraoperative
             complications- iris trauma, vitreous disturbance, descemet's detachment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viraj A Vasavada, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iladevi Cataract &amp; IOL Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iladevi Cataract &amp; IOL Research Centre</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Kruger A, Amon M, Abela-Formanek C, Schild G, Kolodjaschna J, Schauersberger J. Effect of heparin in the irrigation solution on postoperative inflammation and cellular reaction on the intraocular lens surface. J Cataract Refract Surg. 2002 Jan;28(1):87-92.</citation>
    <PMID>11777715</PMID>
  </reference>
  <reference>
    <citation>Rumelt S, Stolovich C, Segal ZI, Rehany U. Intraoperative enoxaparin minimizes inflammatory reaction after pediatric cataract surgery. Am J Ophthalmol. 2006 Mar;141(3):433-7.</citation>
    <PMID>16490487</PMID>
  </reference>
  <reference>
    <citation>Wilson ME Jr, Trivedi RH. Low molecular-weight heparin in the intraocular irrigating solution in pediatric cataract and intraocular lens surgery. Am J Ophthalmol. 2006 Mar;141(3):537-8.</citation>
    <PMID>16490502</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2009</study_first_submitted>
  <study_first_submitted_qc>September 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>September 28, 2009</last_update_submitted>
  <last_update_submitted_qc>September 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Viraj A. Vasavada, MS</name_title>
    <organization>Iladevi Cataract &amp; IOL Research Centre</organization>
  </responsible_party>
  <keyword>Pediatric Cataract Surgery</keyword>
  <keyword>Low-Molecular weight Heparin</keyword>
  <keyword>Intraocular infusion</keyword>
  <keyword>Anti-inflammatory effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

